Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects

Université Laval

$72,150.00

Identification and validation of new therapeutic targets for autoimmune diseases

EF 2011-12

Résumé
Autoimmune diseases such as rheumatoid arthritis and inflammatory bowel diseases (IBD) affect more than one million Canadians. Most autoimmune diseases are the results of misdirected inflammation. Sadly, while the overall mortality rates in the general population has declined substantially over the last decade, patients with autoimmune diseases have not experienced the same improvements in survival. In addition, aging of population contributes to the increase of autoimmune disease cases monitored every year in North America. A better control of chronic inflammation is therefore urgently needed to improve the quality of life of these patients. The pathogenesis of these disorders is not well understood. However, several cytokines have been identified as important players in inflammatory diseases. Indeed, anti-cytokine therapeutic agents have had a profound effect on the treatment of patients with arthritis and IBD. However, 40% of patients with Crohn disease or arthritis, and most with ulcerative colitis do not respond to anti-TNF therapy. Attention has been focused on the well known cytokines to now, but few studies have examined the role of alarmins in these diseases. Alarmins are small intracellular proteins released upon cell necrosis or activation which exhibit cytokine-like activities when released in the extracellular milieu. Examples of alarmins include the High Mobility Group Box-1 and S100A8/A9 proteins. Increasing evidences point toward a pivotal role for alarmins in chronic inflammation and autoimmune diseases in general. In this proposal, we propose to confirm the important role of alarmins in auto immune diseases using two animal models for rheumatoid arthritis and IBD. In brief, we will: 1) Identify new therapeutic targets for the control of chronic inflammation by a combination of proteomic and genomic approaches. We intend to determine cytokine and alarmin release in mouse models of arthritis (collagen-induced arthritis) and inflammatory bowel diseases (TNBS and oxazolone models). DNA chips will allow following cytokine expression at the inflammatory site, while 2D gels, LC-MS/MS and multiplex analyses of serum and tissue samples will determine cytokine and alarmin secretion. 2) Validate the therapeutic targets by examining the effect of candidate neutralizing drugs in the same models. We will identify high affinity peptides binding specifically to the targets identify in the previous section. Because peptides are usually unstable in vivo, we will fused them to the nucleocapsid (NC) of a plant virus (PapMV; papaya mosaic virus) platform to improve its stability. Furthermore, PapMV NC self-assembles into a 20mer disk upon expression in bacteria from which it can be easily purified. The multimerization of the peptide on this platform is likely to improve the avidity of the complex for their target and increase the neutralizing property of the fusion protein as compared to the use of the unstable synthetic peptide. Alternatively, the peptides will be added to the protein cauliflower mosaic virus (CaMV) pIII, which spontaneously forms tetramers. Both proteins have been selected because they have been studied extensively in Dr Leclerc's laboratory, are highly stable, easy to purify in large quantities, resistant to proteases and non-immunogenic in mouse. Efficacy of the immunotherapy drugs will then be tested in the same mouse models of arthritis and inflammatory bowel disease. This research project is a unique collaboration between a researcher investigating autoimmune diseases and a specialist on protein engineering and viral assembly. Together, we have solid experience of mouse models of autoimmune diseases and protein engineering and have access to state-of-the-art genomic and proteomic facilities. A successful outcome will uncover much needed new potential targets for pharmacologic or biologic intervention and further extend our knowledge of the pathogenesis of autoimmune diseases.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
365369-2009
Name nom
Tessier, Philippe
Department département
Microbiologie-infectiologie et d'immunologie
Organization id
51
Institution établissement
Université Laval
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2009
Award amount
72150
Program id
CHRPJ
Program nane en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9000
Research subject group en
Medical sciences
Research subject group fr
Sciences médicales
Research subject en
Medical sciences
Research subject fr
Sciences médicales
Partie
3
Nb partie
3
Application title
Identification and validation of new therapeutic targets for autoimmune diseases
Keyword
NSERC
Application summary
Autoimmune diseases such as rheumatoid arthritis and inflammatory bowel diseases (IBD) affect more than one million Canadians. Most autoimmune diseases are the results of misdirected inflammation. Sadly, while the overall mortality rates in the general population has declined substantially over the last decade, patients with autoimmune diseases have not experienced the same improvements in survival. In addition, aging of population contributes to the increase of autoimmune disease cases monitored every year in North America. A better control of chronic inflammation is therefore urgently needed to improve the quality of life of these patients. The pathogenesis of these disorders is not well understood. However, several cytokines have been identified as important players in inflammatory diseases. Indeed, anti-cytokine therapeutic agents have had a profound effect on the treatment of patients with arthritis and IBD. However, 40% of patients with Crohn disease or arthritis, and most with ulcerative colitis do not respond to anti-TNF therapy. Attention has been focused on the well known cytokines to now, but few studies have examined the role of alarmins in these diseases. Alarmins are small intracellular proteins released upon cell necrosis or activation which exhibit cytokine-like activities when released in the extracellular milieu. Examples of alarmins include the High Mobility Group Box-1 and S100A8/A9 proteins. Increasing evidences point toward a pivotal role for alarmins in chronic inflammation and autoimmune diseases in general. In this proposal, we propose to confirm the important role of alarmins in auto immune diseases using two animal models for rheumatoid arthritis and IBD. In brief, we will: 1) Identify new therapeutic targets for the control of chronic inflammation by a combination of proteomic and genomic approaches. We intend to determine cytokine and alarmin release in mouse models of arthritis (collagen-induced arthritis) and inflammatory bowel diseases (TNBS and oxazolone models). DNA chips will allow following cytokine expression at the inflammatory site, while 2D gels, LC-MS/MS and multiplex analyses of serum and tissue samples will determine cytokine and alarmin secretion. 2) Validate the therapeutic targets by examining the effect of candidate neutralizing drugs in the same models. We will identify high affinity peptides binding specifically to the targets identify in the previous section. Because peptides are usually unstable in vivo, we will fused them to the nucleocapsid (NC) of a plant virus (PapMV; papaya mosaic virus) platform to improve its stability. Furthermore, PapMV NC self-assembles into a 20mer disk upon expression in bacteria from which it can be easily purified. The multimerization of the peptide on this platform is likely to improve the avidity of the complex for their target and increase the neutralizing property of the fusion protein as compared to the use of the unstable synthetic peptide. Alternatively, the peptides will be added to the protein cauliflower mosaic virus (CaMV) pIII, which spontaneously forms tetramers. Both proteins have been selected because they have been studied extensively in Dr Leclerc's laboratory, are highly stable, easy to purify in large quantities, resistant to proteases and non-immunogenic in mouse. Efficacy of the immunotherapy drugs will then be tested in the same mouse models of arthritis and inflammatory bowel disease. This research project is a unique collaboration between a researcher investigating autoimmune diseases and a specialist on protein engineering and viral assembly. Together, we have solid experience of mouse models of autoimmune diseases and protein engineering and have access to state-of-the-art genomic and proteomic facilities. A successful outcome will uncover much needed new potential targets for pharmacologic or biologic intervention and further extend our knowledge of the pathogenesis of autoimmune diseases.